← Leaderboards
Nilofer S. Azad
Johns Hopkins University
$4,756,559
Attributed
$7,131,186
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,131,186 · 6
By mechanism
T32$2,541,049 · 1
R01$2,208,206 · 2
P01$1,537,715 · 1
P30$461,915 · 1
R21$382,301 · 1
Top collaborators
- Mary Y. Armanios5 shared
- Gregory B. Lesinski4 shared
- Neeha Zaidi1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Elizabeth Marion Jaffee$29,780,612
- Dung T Le$5,608,820
- William Ramses Bishai$43,237,711
- Ben H Park$14,510,999
- Cesar Augusto Santa-Maria$1,330,670
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsFundingMalignant NeoplasmsPre-ClinicalProgramsTranslatingResponseSignal TransductionTumorMediatingBiopsySignal PathwayIn Vivo ModelInvestigationCollaborationsImmunoregulationImmunotherapyT-LymphocyteBiological MarkersImmune Checkpoint InhibitorMolecularImmuneEpigenetic ProcessCells
Grant awards (21)
Optimization of an active mutant KRAS peptide vaccine in colorectal cancer$589,838
R01 · FY2025 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$551,558
T32 · FY2025 · CA
Mechanisms of immunomodulation with epigenetic therapy$313,219
P01 · FY2025 · CA · contact PI
Cancer Genetics and Epigenetics$299,087
P30 · FY2025 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$502,474
T32 · FY2024 · CA
Mechanisms of immunomodulation with epigenetic therapy$297,559
P01 · FY2024 · CA · contact PI
Cancer Genetics and Epigenetics$54,276
P30 · FY2024 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$445,306
T32 · FY2023 · CA
Mechanisms of immunomodulation with epigenetic therapy$306,956
P01 · FY2023 · CA · contact PI
Cancer Genetics and Epigenetics$54,276
P30 · FY2023 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$435,870
T32 · FY2022 · CA
Mechanisms of immunomodulation with epigenetic therapy$306,762
P01 · FY2022 · CA · contact PI
Cancer Genetics and Epigenetics$54,276
P30 · FY2022 · CA · contact PI
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$412,434
R01 · FY2021 · CA
Mechanisms of immunomodulation with epigenetic therapy$313,219
P01 · FY2021 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$605,841
T32 · FY2020 · CA
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$424,213
R01 · FY2020 · CA
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$390,583
R01 · FY2019 · CA
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$391,138
R01 · FY2018 · CA
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer$170,891
R21 · FY2014 · CA · contact PI
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer$211,410
R21 · FY2013 · CA · contact PI